Cargando…

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease

Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Millan, Belen, Diaz de la Guardia, Rafael, Roca-Ho, Heleia, García-Herrero, Carmen M, Lavoie, Jessie R, Rosu-Myles, Michael, Gonzalez-Rey, Elena, O'Valle, Francisco, Criado, Gabriel, Delgado, Mario, Menendez, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336556/ https://www.ncbi.nlm.nih.gov/pubmed/28154372 http://dx.doi.org/10.1038/emm.2016.143

Ejemplares similares

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide
por: Davis, David A., et al.
Publicado: (2017)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2017)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson’s Disease
por: Casu, Maria Antonietta, et al.
Publicado: (2020)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells
por: Petazzi, Paolo, et al.
Publicado: (2020)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
por: Lopez-Millan, Belen, et al.
Publicado: (2019)

The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
por: Kibata, Kayoko, et al.
Publicado: (2019)

Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation
por: Rodriguez, Rene, et al.
Publicado: (2014)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202
por: Voorhees, P., et al.
Publicado: (2022)

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Immunomodulatory nano-preparations for rheumatoid arthritis
por: Li, Chenglong, et al.
Publicado: (2022)

Immunomodulatory roles of metalloproteinases in rheumatoid arthritis
por: Bian, Yanqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uj86hd6oet1d2aplc84ltu2qdf